Novo Nordisk's Victoza gets EU market green light
COPENHAGEN, July 3 (Reuters) - Danish pharmaceuticals group Novo Nordisk's (NOVOb.CO: Quote, Profile, Research) diabetes treatment Victoza has won European Commission approval for marketing across the EU, the company said on Friday.
"The European Commission has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults," Novo Nordisk said in a statement, calling it an "important milestone."
The company will launch Victoza in the UK, Germany and Denmark this summer and in other European markets in the second half of 2009 and throughout 2010, it said.
"The marketing approval in Europe does not change Novo Nordisk's expectations for the company's financial results for 2009," it added.
© Thomson Reuters 2009 All rights reserved
One Year Later
Mumbai held tearful memorials and police staged a show of strength as it marked the first anniversary of militant raids that killed 166 people and ratcheted up tensions with Pakistan. Slideshow | Full Coverage
Liberhan Commission Report
The government published a long awaited report, recently leaked, accusing BJP leaders of a role in the 1992 destruction of the Babri mosque in Ayodhya. Full Article
